Current status of cediranib: the rapid development of a novel anti-angiogenic therapy.
about
Receptor tyrosine kinase-mediated angiogenesisRole of vascular endothelial growth factor inhibitors in the treatment of gynecologic malignancies.Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action?Development of second-generation VEGFR tyrosine kinase inhibitors: current status.Combination testing of cediranib (AZD2171) against childhood cancer models by the pediatric preclinical testing program.Cediranib inhibits both the intraosseous growth of PDGF D-positive prostate cancer cells and the associated bone reactionThe VEGF pathway in cancer and disease: responses, resistance, and the path forward.Molecular targeted therapy for advanced gastric cancerAdvances in the design and synthesis of prazosin derivatives over the last ten years.Targeting angiogenesis in childhood sarcomas.XELOX in colorectal cancer: a convenient option for the future?Targeting the growth factors and angiogenesis pathways: small molecules in solid tumors.Novel targeted agents for gastric cancer.Beyond bevacizumab: investigating new angiogenesis inhibitors in ovarian cancer.Molecular targeted agents for gastric cancer: a step forward towards personalized therapy.Clinical management of advanced gastric cancer: the role of new molecular drugs.Angiogenesis inhibitors in gastric and gastroesophageal junction cancer.Phase I, pharmacokinetic and pharmacodynamic evaluation of CYT997, an orally-bioavailable cytotoxic and vascular-disrupting agent.Antiangiogenesis therapy in the treatment of metastatic colorectal cancer.
P2860
Q27001612-41E39A3F-4ADF-434D-8C4C-678E9A695107Q33771212-2F5081EB-B544-4725-9410-0F53E993BC9DQ34088265-7347D9EA-9B77-4CEC-8A26-08EB14FED51CQ34616440-6903CC92-41F7-4BF1-9AE9-DBD61314F5EDQ35659433-E8FE5C3D-8540-408A-8EA0-979CD558E71CQ36013452-A22EA11B-6BAB-4843-9588-84E236639752Q36526512-83966DCE-DA20-41A7-886E-E096913D21E0Q36705689-0D1F91F5-D0CD-4A36-A2D6-3B58C638B91CQ36827500-43979C1E-7386-4F7E-91EC-2057B20FE0FFQ37825441-470B3149-0D83-4A0B-A4DB-B4206451EFB2Q37839084-49A538D8-A764-43D7-8954-16E0763ABDD3Q37863629-981EFBA5-AC67-4AA0-98D3-11DB439C43A1Q38019657-F8EEE7F1-5BC9-4398-8A1A-78A2971E80DCQ38151193-F7916F8F-2738-4675-9C80-EC4AE6E2C109Q38161727-7BDF5826-4F68-4A7E-9EEA-F2A64AECEE77Q38263841-3F4EEF3D-9770-4E07-B29D-48F12897997BQ38578404-A48A4CF6-852A-49AF-9B4C-635F806DEFE8Q39636226-3143123F-1BCC-461B-BAE0-CE1F85560883Q42402968-8964794F-AF6F-4295-A790-6A26E0261F81
P2860
Current status of cediranib: the rapid development of a novel anti-angiogenic therapy.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on May 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Current status of cediranib: the rapid development of a novel anti-angiogenic therapy.
@en
Current status of cediranib: the rapid development of a novel anti-angiogenic therapy.
@nl
type
label
Current status of cediranib: the rapid development of a novel anti-angiogenic therapy.
@en
Current status of cediranib: the rapid development of a novel anti-angiogenic therapy.
@nl
prefLabel
Current status of cediranib: the rapid development of a novel anti-angiogenic therapy.
@en
Current status of cediranib: the rapid development of a novel anti-angiogenic therapy.
@nl
P2860
P356
P1433
P1476
Current status of cediranib: the rapid development of a novel anti-angiogenic therapy
@en
P2093
Colin R Lindsay
Jim Cassidy
P2860
P304
P356
10.2217/FON.09.18
P407
P577
2009-05-01T00:00:00Z